查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1247441

2023-2030 年全球免疫組織化學市場

Global Immunohistochemistry Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

預計到 2022 年，全球免疫組織化學市場規模將達到 23.0279 億美元，到 2030 年將達到 42.4065 億美元，預測期內（2023-2030 年）的複合年增長率為 8.1%。

抗體用於在稱為免疫組織化學 (IHC) 的過程中識別組織片段（例如，肝臟、胰腺、心臟）內細胞中的蛋白質（抗原）。 當組織樣本到達實驗室進行疾病檢測時，一些特徵很難識別。 不同的疾病和疾病亞型表現不同，可能需要不同的治療，即使它們在顯微鏡下看起來可能包含相同大小和形狀的細胞。 區分這些細胞的最有效方法是尋找充當細胞標記的特定分子。

市場動態

推動全球免疫組織化學市場的主要因素是癌症發病率和患病率的增加、IHC 檢測的報銷潛力以及 IHC 技術進步帶來的市場擴張。

癌症發病率和患病率的上升預計將推動市場的增長。

癌症的日益流行以及免疫組織化學在診斷感染、心血管疾病和其他疾病方面的流行都與這個市場的相當大的份額有關。 根據世界衛生組織 2022，癌症是一個廣義術語，指的是可以影響身體任何部位的任何疾病。 使用的其他術語包括惡性腫瘤和贅生物。 到 2020 年，癌症將成為全球第一大死因，估計死亡人數將達到 1000 萬人，即每 6 人中就有 1 人死亡。

典型的癌症包括乳腺癌、肺癌、結腸癌、直腸癌和前列腺癌。 大約三分之一的癌症相關死亡是由吸煙、高體重指數、飲酒、飲食中水果和蔬菜含量低以及缺乏鍛煉引起的。

根據美國國立衛生研究院的數據，到 2020 年，估計美國將診斷出 1,806,590 例新癌症病例，606,520 人將死於該病。 最常見的癌症是乳腺癌、肺癌和支氣管癌、前列腺癌、結腸癌和直腸癌、皮膚黑色素瘤、膀胱癌、非霍奇金淋巴瘤、腎臟和腎盂癌、子宮內膜癌、白血病、胰腺癌、甲狀腺癌和肝癌（按 2020 年新增病例估計數降序排列）。 這些癌症疾病增加了對免疫化學工具的需求。

熟練病理學家的短缺預計會阻礙市場增長。

然而，缺乏訓練有素的病理學家是市場擴張的製約因素。 病理學家使用自動化 IHC 平台對石蠟切片進行免疫組織化學 (IHC) 染色，應用適當的抗原修復技術，並解決設備損壞和染色效果差的問題。 如果沒有病理學家，這是不可能的。 未經培訓的技術人員是市場的障礙。

COVID-19 影響分析

很明顯，SARS-CoV-2 的爆發可能是市場擴張的機會。 許多學術機構和生物製藥公司正在努力將免疫熒光分析轉化為有用的診斷工具。 COVID-19 流行病給全球供應網絡造成了重大障礙。 許多全國性的封鎖仍在繼續，擾亂或暫時中斷了原材料和成品的流動，影響了製造過程。

然而，免疫組織化學和原位雜交方法已經能夠在福爾馬林固定石蠟包埋 (FFPE) 標本中檢測 SARS-CoV 和 SARS-CoV-2 病毒產物，該標本將於 2020 年發表。根據 12 月自然雜誌的一期，在未來將具有不可估量的價值。 在動物模型中研究冠狀病毒病原體和治療研究可以利用這些不同的方法進行病毒檢測和材料合成。

此外，COVID-19 大流行影響了免疫組織化學試劑盒和試劑的可用性，我們預測未來幾年用於 COVID-19 研究和診斷的需求量很大。事實一直如此。

內容

第 1 章研究方法和範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第四章市場動態

  • 市場影響因素
    • 司機
      • 癌症發病率和患病率增加
      • IHC 測試報銷的可能性
    • 阻止因素：
      • 熟練病理學家的短缺預計會阻礙市場增長
    • 商機
    • 影響分析

第五章行業分析

  • 波特的五力分析
  • 供應鏈分析
  • 價格分析
  • 監管分析

第 6 章 COVID-19 分析

  • 市場上 COVID-19 的分析
    • 在 COVID-19 市場情景之前
    • 當前的 COVID-19 市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格和動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 結論

第 7 章副產品

  • 抗體
    • 試劑
      • 組織染色
      • 封閉血清/試劑
      • 固定化試劑
      • 顯色底物
      • 蛋白□
      • 有機溶劑
      • 稀釋劑
      • 其他
    • 設備
      • 載玻片染色系統
      • 載玻片掃描儀
      • 組織處理系統
      • 其他
    • 工具包
      • 動物 IHC 試劑盒
      • 人類 IHC 試劑盒

第八章應用

  • 診斷
  • 藥物測試
  • 法醫申請
  • 其他

第 9 章最終用戶

  • 醫院
  • 診斷實驗室
  • 學術和研究機構等
  • 其他

第10章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第11章競爭格局

  • 主要發展和戰略
  • 公司股票分析
  • 產品基準
  • 知名大公司名單

第12章公司簡介

  • 丹納赫公司
    • 公司簡介
    • 產品組合和說明
    • 主要亮點
    • 財務摘要
  • F. Hoffmann-La Roche Ag.
  • BD
  • Agilent Technologies, Inc.
  • Merck Kgaa
  • Bio-Rad Laboratories, Inc.
  • BioGenex
  • Abcam Plc
  • Candor Bioscience Gmbh
  • PerkinElmer, Inc.

第13章 DataM

簡介目錄
Product Code: PH3182

Market Overview

The global Immunohistochemistry market size was valued at US$ 2,302.79 million in 2022 and is estimated to reach US$ 4,240.65 million by 2030, growing at a CAGR of 8.1% during the forecast period (2023-2030).

Antibodies are employed in the process known as immunohistochemistry (IHC) to recognize proteins (antigens) in cells within a tissue segment (for instance, liver, pancreas or heart). Several characteristics are challenging to ascertain when a tissue sample is delivered to a lab for disease testing. Even if they may appear to contain identical cells in size or shape under a microscope, various diseases or disease subtypes may behave differently and call for different treatments. The most effective way to distinguish between these cells is to look for particular molecules that act as markers on them.

Market Dynamics

The major factors driving the global Immunohistochemistry market the market will expand as the growing incidence and prevalence of Cancer, availability of reimbursements for IHC tests and technological advancements in IHC.

Growing incidence and prevalence of Cancer are expected to drive the market's growth.

The growing prevalence of Cancer and the widespread use of immunohistochemistry in diagnosing infectious diseases, cardiovascular disorders, and other diseases are both associated with a substantial share of this market. According to World Health Organization 2022, Cancer is a broad term that refers to any disease that can affect any body part. Other terms used include malignant tumors and neoplasms. Cancer will be the leading cause of mortality worldwide in 2020, with an estimated 10 million deaths, or approximately one in every six.

The most common forms of Cancer include breast, lung, colon, rectum, and prostate. About one-third of cancer-related deaths are caused by smoking, high body mass index, consuming alcohol, eating few fruits and vegetables, and not exercising.

And according to the National Institutes of Health, in 2020, an estimated 1,806,590 new cases of Cancer will be diagnosed in the United States, and 606,520 people will die from the disease. The most common cancers (listed in descending order according to estimated new cases in 2020) are breast cancer, lung and bronchus Cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, non-Hodgkin lymphoma, kidney and renal pelvis cancer, endometrial Cancer, leukemia, pancreatic Cancer, thyroid cancer, and liver cancer. These conditions of cancer disorders increase the demand for immunochemistry tools.

Lack of skilled pathologists is expected to hamper the market's growth.

However, the market expansion is constrained by the absence of well-trained pathologists. The pathologist uses an automated IHC platform to carry out immunohistochemistry (IHC) stains on paraffin sections, applies the proper antigen retrieval methods, and resolves problems with broken equipment and subpar stains. And without the pathologist, it would not have been possible; untrained technicians are a hindrance to the market.

COVID-19 Impact Analysis

The SARS-CoV-2 outbreak became apparent as a potential window of opportunity for market expansion. Numerous academic institutions and biopharmaceutical businesses are examining the immunofluorescence assay to make it a useful diagnostic tool. The COVID-19 epidemic has caused significant barriers to global supply networks. Numerous nationwide lockdowns continue to impede or even temporarily block the flow of raw materials and completed goods, impacting the manufacturing process.

However, immunohistochemistry and in situ hybridization methods enable the detection of SARS-CoV and SARS-CoV-2 viral products in formalin-fixed paraffin-embedded (FFPE) specimens will be immensely valuable in the future, according to the Nature magazine, December 2020. Studies of coronavirus pathogenesis and therapeutic research in animal models can use these varied methods for virus detection and material synthesis.

Furthermore, the COVID-19 pandemic affected the availability of immunohistochemistry kits and reagents, yet, their use in COVID-19 research and diagnosis is predicted to enhance its demand in the coming years.

Segment Analysis

The diagnostics segment is expected to grow at the fastest CAGR during the forecast period (2023-2030)

The application segment is the highest market holder in the global immunohistochemistry market. Numerous market players' launches of new products, viral outbreaks, the prevalence of chronic diseases around the world, an increase in point-of-care diagnostics, and quickly advancing technology are major drivers of the segment's growth. The industry and academia continue to find the field appealing despite its rapid evolution. The development and subsequent administration of tailored medication using diagnostic techniques are projected to accelerate market expansion.

In addition, several market players engage in strategic initiatives. For instance, in January 2021, Diaceutics PLC, a company that offers diagnostic tracking, laboratory mapping, testing, and other services, announced a strategic partnership with Canadian Pathology Quality Assurance, a non-profit organization, to advance the development of Neurotrophic Tropomyosin Receptor Kinase (NTRK) IHC proficiency testing. And in June 2021, Amoy Diagnostics Co. Ltd., Riken Genesis Co. Ltd., and Precision Medicine Asia Co. Ltd. released the AmoyDx Pan Lung Cancer PCR Panel. The Ministry of Health, Labour, and Welfare (MHLW) has given the panel the go-ahead for marketing and production in Japan.

Geographical Analysis

North America holds the largest market share in the global Immunohistochemistry market.

North America dominates the global Immunohistochemistry market primarily due to factors like the presence of major companies, the high prevalence of Cancer and other chronic diseases in the area, and the well-established healthcare infrastructure are only a few of the major factors responsible for the market's growth. The existence of significant market participants, the ease with which IHC solutions are accessible, the increased use of technologically advanced IHC instruments, and the arrival of newer IHC solutions all contribute to the market expansion in the North American region.

For instance, in March 2022, Boston Cell Standards, a company dedicated to ensuring that cancer patients receive accurate diagnosis and treatment, announced that it launched the Consortium for Analytic Standardization in Immunohistochemistry (CASI). The new organization is led by an international panel of pathologists and scientists dedicated to improving patient immunohistochemistry (IHC) test accuracy and reproducibility. And in June 2021, PathAI, a U.S.-based provider of AI-powered technology for pathological applications, presented a machine learning-based quality control tool developed for HER2 testing in breast cancer in June 2021 at the American society of clinical oncology virtual scientific program 2021.

Competitive Landscape

The Immunohistochemistry market is moderately competitive with local and global companies' presence. Danaher Corporation, F. Hoffmann-La Roche Ag., BD, Agilent Technologies, Inc., Merck Kgaa, Bio-Rad Laboratories, Inc., BioGenex, Abcam Plc, Candor Bioscience Gmbh, PerkinElmer, Inc. and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in December 2021, according to BioGenex, a company that develops, produces, and distributes molecular pathology systems for tumor diagnosis, prognosis, precision medicine, and life science research, three new primary immunohistochemistry (IHC) antibodies for cancer diagnosis have been published. These are CD56, CD163, and CD8A, respectively.

BioGenex.

Overview: BioGenex creates, develops, and sells molecular pathology systems for life science research, precision medicine, and tumor detection and prognosis. Pathology is being revolutionized by BioGenex's market-leading next-generation cytogenetic FISH workflow solution and miRNA system for the characterisation of Cancer of Unknown Primary (CUP) and undifferentiated tumors. The most cutting-edge systems are proprietary fully automated molecular pathology workstations from BioGenex..

Product Portfolio:

IHC Detection Kits: Immunohistochemistry (IHC) Detection Systems are specially designed for the chromogenic detection of antigen-antibody binding reactions with primary antibodies of various sources (mouse or rabbit, IgG or IgM).

The global Immunohistochemistry market report would provide access to approx.: 45+market data table, 40+figures and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing incidence and prevalence of Cancer.
      • 4.1.1.2. Availability of reimbursements for IHC tests.
    • 4.1.2. Restraints:
      • 4.1.2.1. Lack of skilled pathologist is expected to hamper the market's growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Supply Chain Analysis
  • 5.3 Pricing Analysis
  • 5.4 Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 7.1.2. Market Attractiveness Index, By Product
  • 7.2. Antibodies
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
    • 7.2.3. Reagents
      • 7.2.3.1. Histological Stains
      • 7.2.3.2. Blocking Sera and Reagents
      • 7.2.3.3. Fixation Reagents
      • 7.2.3.4. Chromogenic Substrates
      • 7.2.3.5. Proteolytic Enzymes
      • 7.2.3.6. Organic Solvents
      • 7.2.3.7. Diluents
      • 7.2.3.8. Other
    • 7.2.4. Equipment
      • 7.2.4.1. Slide Staining Systems
      • 7.2.4.2. Slide Scanners
      • 7.2.4.3. Tissue Processing Systems
      • 7.2.4.4. Other
    • 7.2.5. Kits
      • 7.2.5.1. Animal IHC Kits
      • 7.2.5.2. Human IHC Kits

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Diagnostics
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
  • 8.3. Drug Testing
  • 8.4. Forensic Application
  • 8.5. Others

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospitals
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis US$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030
  • 9.3. Diagnostic Laboratories
  • 9.4. Academic & Research Institutes
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size AnalysisUS$ Million, 2021-2030 and Y-o-Y Growth Analysis (%), 2022-2030, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Products Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1. Danaher Corporation
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. F. Hoffmann-La Roche Ag.
  • 12.3. BD
  • 12.4. Agilent Technologies, Inc.
  • 12.5. Merck Kgaa
  • 12.6. Bio-Rad Laboratories, Inc.
  • 12.7. BioGenex
  • 12.8. Abcam Plc
  • 12.9. Candor Bioscience Gmbh
  • 12.10. PerkinElmer, Inc.

LIST NOT EXHAUSTIVE

13. Global Immunohistochemistry Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Application
  • 13.3. Contact Us